Enlivex’s Phase II Trial Reveals Promising Results for Allocetra in Sepsis Patients

Your TitleDatePromising Results Revealed in Enlivex s Phase II Trial of Allocetra in Sepsis PatientsNes-Ziona, Israel Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a leading clinical-stage macrophage reprogramming immunotherapy company, has announced optimistic findings from its Phase II study of Allocetra in patients suffering from sepsis. The trial, which enrolled 120 participants, showcased encouraging indications of efficacy and safety. The results provide a glimmer of hope for millions of patients worldwide who are affected by sepsis, a life-threatening condition with limited treatment options.Sepsis is a severe immune response to infection that can result in organ dysfunction and failure. Despite advancements in medical science, sepsis remains a significant cause of mortality and morbidity globally, with limited effective treatments available. Enlivex s Phase II study aimed to evaluate Allocetra, the company s innovative immunotherapy candidate, as a potential treatment option for sepsis.

Comments